復䢇醫療科技有限公司* Sisram Medical Ltd 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 於本公告日期，本公司董事會成員包括執行董事Lior Moshe DAYAN先生及李家 宏先生；非執行董事劉毅先生、馮蓉麗女士及Caroline Xiaokui JIN女士；獨立非 執行董事方香生先生、陳志峰先生、陳怡芳女士及廖啟宇先生。 （ 於 以 色 列 註 冊 成 立 的 有 限 公 司 ） （股份代號：1696） 自願公告 本公告乃由復銳醫療科技有限公司（「本公司」）自願發佈。 本公司欣然宣佈旗下獲再授權注射用A型肉毒毒素（DaxibotulinumtoxinA-lanm， 中國境內商標達希斐®，英文商標DAXXIFY®，項目代號RT002，以下簡稱「達希 斐」）已通過中華人民共和國（「中國」）食品藥品檢定研究院質量標準檢驗。該產品 適用於暫時性改善成人因皺眉肌和╱或降眉間肌活動引起的中度至重度眉間紋。 截至本公告發佈之日，於中國境內尚 ...

IT之家 12 月 26 日消息，回看谷歌眼镜的失败，谷歌联合创始人谢尔盖・布林直言，当年的自己过于自信，甚至把自己当成"下一个史蒂夫・乔布斯"，结果 在产品尚未成熟时就急于将其推向市场。 2012 年，谷歌曾向少数用户推出谷歌眼镜。这款没有传统镜片的智能眼镜并非行业首创，却迅速成为最具知名度的代表。然而，谷歌眼镜几乎一上市就遭 遇商业失败，这段经历至今仍被布林铭记。 报道提到，苹果同样经历过类似挫折。被史蒂夫・乔布斯在 1997 年终止的苹果掌上电脑"Newton"与谷歌眼镜有着惊人的相似之处：走在时代前沿、价格高 昂，最终未被市场接受。 据外媒 AppleInsider 今晚报道，在斯坦福大学工程学院百年纪念活动上，布林以谷歌眼镜为例，向年轻创业者分享了教训。他表示，产品创意再新颖，也应 在真正成熟之后再进行高调展示。 谷歌眼镜当年的问题十分明显。当时的用户认为该产品外观设计怪异笨重，内置的 500 万像素摄像头更是引发了隐私担忧，高达 1500 美元的定价同样令消 费者望而却步，折算到今天约为 2120 美元（IT之家注：现汇率约合 14873 元人民币）。 布林坦承，当年在成本控制和产品打磨上都没有做 ...

Core Viewpoint - Weichai Power (000338) expresses confidence in the market potential and application areas of SOFC products, emphasizing its commitment to commercializing these products in response to global customer needs [1] Group 1 - The company highlights the broad market prospects for SOFC products [1] - The company plans to leverage its strong technological foundation to meet market trends [1] - The company aims to continue advancing the mass commercialization of SOFC products [1]

Group 1: Company Research and Development - The company has its own research center and collaborates extensively with external universities and research institutions [1] - Currently, the solid-state battery membrane is in the small-scale sample delivery phase, with no mass production or substantial sales yet [1] Group 2: Product Applications and Market Focus - The company's products are based on ultra-fine fiber technology, focusing on industrial fabric applications [1] - The company is optimistic about future growth, particularly in sportswear fabrics, automotive interior fabrics, and electronic product fabrics [2] Group 3: Product Development and Commercialization - Samples of bio-inspired muscle fibers are available, and the company is conducting applied research with leading robotics manufacturers, but no mass production or revenue has been generated yet [2] - The company has been testing hydrogen separation membrane samples since last year and aims to expedite the commercialization process [2] Group 4: Financial Strategy and Future Plans - The company will formulate future funding plans based on its needs, especially after a major shareholder transferred equity to an industry partner [2]

Core Viewpoint - Boyu Capital has increased its stake in Shanghai Henlius Biotech, Inc. by purchasing 262,500 and 80,000 H-shares, raising its holding from 5.84% to 7% [1][2]. Group 1: Investment Activity - Boyu Capital previously invested HKD 21.27 million to increase its stake from 4.89% to 5.15% on June 18, 2023, crossing the 5% threshold [2]. - The recent purchases reflect Boyu Capital's confidence in the core value and sustainable development potential of Shanghai Henlius in the innovative biopharmaceutical sector [2][3]. Group 2: Product Development and Clinical Progress - Shanghai Henlius has a robust pipeline with key products such as the anti-PD-1 monoclonal antibody Hansizhuang and the PD-L1 ADC HLX43, which have received international recognition for their clinical value [2][3]. - Recent data presented at the "2025 International Lung Cancer Frontier and Innovation Forum" confirmed the efficacy of HLX43 and HLX07, further enhancing market confidence in the company's R&D capabilities [3][5]. Group 3: Commercialization and International Collaboration - The company has established a diverse product matrix and has received global approvals for nine products, with four applications accepted by regulatory agencies in China, the US, and Europe [5]. - Shanghai Henlius has formed commercial partnerships with over 20 international pharmaceutical companies, covering major markets in Europe and the US, which supports its revenue growth [6]. - The company reported a significant increase in overseas product profits, with a 280% year-on-year growth in cash flow from BD contracts, indicating strong future revenue potential [6]. Group 4: Industry Outlook - As the biopharmaceutical industry enters a phase of high-quality development, companies with strong R&D capabilities and mature commercialization systems will become increasingly competitive [8]. - The continuous investment by top-tier capital like Boyu Capital serves as a testament to the intrinsic value demonstrated by Shanghai Henlius through solid clinical data [8].

Financial Performance - In Q3 2025, the company achieved a revenue of CNY 670 million, a year-on-year increase of 7.70%, and a net profit of CNY 185 million, up by 6.56% [3] - For the first nine months of 2025, the company reported a revenue of CNY 1.963 billion, a year-on-year growth of 2.15%, while net profit decreased by 6.48% to CNY 551 million [3] - The growth in Q3 revenue and net profit was primarily driven by increased sales of growth hormones and antibody drugs [3] Product Development and Clinical Trials - The PA3-17 injection from the company's affiliate, Boshengji, is in Phase II clinical trials and aims for conditional market approval [3] - The "AK2017 injection" (recombinant human growth hormone-Fc fusion protein) has completed Phase II clinical trial enrollment and is expected to start Phase III trials in early 2026 [4] - The "HuA21 injection," targeting HER2, showed an objective response rate (ORR) of 80.8% in the 30 mg/kg group during exploratory studies [5] - The "HK010 injection" (PD-L1*4-1BB) is in Phase I clinical trials, showing good efficacy and safety in various cancers [9] Market Strategy and Future Outlook - The company plans to enhance operational efficiency and solidify the growth of its core business while accelerating the development of other business areas [3] - The collaboration with Weisheng Pharmaceutical on the long-acting growth hormone aims to penetrate the high-end market, enhancing product visibility and sales [4] - The company anticipates a market size exceeding CNY 4 billion for follicle-stimulating hormone in 2025, with plans to capture significant market share [10] - Sales and R&D expenses are expected to increase slightly over the next two years due to the rise in innovative drug trials and new product launches [11] Strategic Initiatives - The company has established an innovation research institution in Shanghai to support the development of self-researched and commercially cooperative products [12] - Plans for expanding production capacity include new production lines in northern and eastern regions, expected to contribute to economic growth [12]

Group 1 - The company has made significant progress with its S600E product, having received patent approval from the China National Intellectual Property Administration in April 2019 [1] - The China National Standardization Management Committee published the national product standard GB/T37430-2019 for S600E in May 2019 [1] - A processing plant with an annual production capacity of approximately 500,000 tons for S600E was inaugurated in Henan Province in June 2019 [1] Group 2 - The company signed a sales agency agreement with a third-party steel company on July 29, 2019, allowing the third party to sell the full range of S600E products in designated areas of China for a three-year term, extendable until June 30, 2036 [1] - The company aims to further enhance its financial position and operational performance through the commercialization of S600E usage by licensing the patent to third-party manufacturers [1] - The company's shares remain suspended from trading [2]

Core Viewpoint - The strategic investment by Haiqing Pharmaceutical in Mengke Pharmaceutical marks a significant shift in the latter's ownership structure, with Haiqing becoming the controlling shareholder and aiming to enhance Mengke's capabilities in the antibiotic drug development sector [1][3][4]. Financing and Ownership Changes - Mengke Pharmaceutical plans to raise 1.033 billion yuan through a private placement of 164 million shares at a price of 6.3 yuan per share, which will be used for daily research and operational expenses [3][4]. - Following the issuance, Haiqing Pharmaceutical will hold a 20% stake in Mengke and will nominate five directors to the board, giving it majority control [1][3]. - This marks the first private placement since Mengke's IPO in August 2022, which raised 1.061 billion yuan [3][4]. Financial Performance - From 2021 to mid-2025, Mengke Pharmaceutical generated total revenue of 344 million yuan but incurred a net loss of 1.447 billion yuan, with total R&D expenses amounting to 1.132 billion yuan [6][7]. - The company has not yet achieved profitability, with significant losses reported each year since its product commercialization began in 2021 [6][7]. Strategic Collaboration - A strategic cooperation agreement has been signed between Mengke and Haiqing, focusing on leveraging Mengke's expertise in multi-drug resistant bacteria and Haiqing's established R&D and commercialization capabilities [4][7]. - The collaboration aims to enhance both companies' core competitiveness and facilitate the commercialization of Mengke's products, particularly in the antibiotic sector [4][7]. Market Reaction - Following the announcement of the private placement and strategic partnership, Mengke Pharmaceutical's stock price surged by 20.02%, closing at 9.71 yuan per share [5]. Future Projections - If the collaboration is successful, Mengke aims to achieve sales revenue targets of 260 million yuan, 388 million yuan, and 600 million yuan for the years 2026, 2027, and 2028, respectively [7].

Core Viewpoint - Mengke Pharmaceutical plans to raise no more than 1.033 billion yuan through a targeted private placement, with the funds allocated entirely for daily research and operational investments [1][2] Group 1: Fundraising and Shareholding Changes - The targeted placement will involve Nanjing Haiqing Pharmaceutical Co., which will acquire a 20% stake in Mengke Pharmaceutical, making it the controlling shareholder and changing the company's previous status of having no controlling shareholder [1][3] - The fundraising aims to supplement operational funds, promote business development, ensure research investment, and enhance the company's core competitiveness [2] Group 2: Strategic Cooperation and Industry Position - Mengke Pharmaceutical and Haiqing Pharmaceutical signed a strategic cooperation agreement to collaborate in product commercialization, production synergy, research innovation, and capital cooperation [4] - Haiqing Pharmaceutical, as an industrial investor, is expected to enhance Mengke Pharmaceutical's commercialization capabilities and improve sales scale and efficiency [5] Group 3: Research and Development Pipeline - Mengke Pharmaceutical has several antibacterial new drugs in clinical development, including MRX-4 and MRX-8, which require substantial funding for their advancement [2][6] - The funds raised will accelerate the development of the company's research pipeline and facilitate the commercialization of research outcomes [6]

Core Viewpoint - The company reported significant revenue growth and advancements in its product pipeline for the treatment of structural heart diseases, indicating a strong foundation for future growth [1]. Financial Performance - The company achieved revenue of 13.426 million RMB for the six months ending June 30, 2025, compared to no revenue in the same period last year [1]. - Gross profit reached 11.827 million RMB, also showing an increase from zero in the previous year [1]. - Research and development expenses amounted to 88.885 million RMB [1]. Product Development - The company made substantial progress in its product pipeline for treating tricuspid, aortic, and mitral valve diseases, resulting in a diversified and high-potential product portfolio [1]. - The commercialization of interventional products for treating structural heart diseases has been a key driver of revenue growth [1]. Strategic Initiatives - The company is intensifying its international business expansion efforts to enhance product influence and clinical application scale, laying a solid foundation for long-term high-speed growth [1].